Literature DB >> 20890767

Increased risk of death in pediatric and adult patients with ESRD secondary to lupus.

Sangeeta Sule1, Barbara Fivush, Alicia Neu, Susan Furth.   

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that can cause significant kidney disease. Our goal was to assess the relative mortality risk associated with SLE in pediatric and adult populations with end-stage renal disease (ESRD) maintained on hemodialysis (HD). We performed Kaplan-Meier survival analysis from data collected by the United States Renal Data System (USRDS) in strata of pediatric and adult patients. This file includes data on all Medicare-reimbursed renal replacement patients. Cox proportional hazard models were used to assess mortality after adjusting for race and gender. Subjects were censored at transplantation or at end of follow-up. Pediatric patients with ESRD secondary to SLE had a 2-fold increased risk of death compared with other pediatric patients with ESRD (hazard ratio [HR]: 2.4, 95% confidence interval [CI]: 1.5-3.7). Adult patients with ESRD secondary to SLE were also at increased risk of death compared with other adult patients (HR: 1.7, 95% CI: 1.2-2.7). The most common causes of death in both pediatric and adult patients with SLE were cardiovascular disease and cardiac arrest. Our study demonstrates that there is a significant increase in mortality secondary to cardiovascular disease in pediatric and adult patients with ESRD secondary to SLE. Patients with ESRD secondary to SLE may need aggressive monitoring for traditional risk factors for atherosclerosis and the diagnosis of SLE alone may be an independent risk factor for death in patients with ESRD.

Entities:  

Mesh:

Year:  2010        PMID: 20890767      PMCID: PMC2992078          DOI: 10.1007/s00467-010-1640-9

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

Review 1.  Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis?

Authors:  S Van Doornum; G McColl; I P Wicks
Journal:  Arthritis Rheum       Date:  2002-04

2.  Longterm followup of childhood lupus nephritis.

Authors:  Stefan Hagelberg; Yuna Lee; Joanne Bargman; Gordon Mah; Rayfel Schneider; Carl Laskin; Allison Eddy; Dafna Gladman; Murray Urowitz; Diane Hebert; Earl Silverman
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

3.  Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus.

Authors:  J M Esdaile; M Abrahamowicz; T Grodzicky; Y Li; C Panaritis; R du Berger; R Côte; S A Grover; P R Fortin; A E Clarke; J L Senécal
Journal:  Arthritis Rheum       Date:  2001-10

4.  Elevation of tumor necrosis factor-alpha and increased risk of recurrent coronary events after myocardial infarction.

Authors:  P M Ridker; N Rifai; M Pfeffer; F Sacks; S Lepage; E Braunwald
Journal:  Circulation       Date:  2000-05-09       Impact factor: 29.690

5.  Nephrotic-range proteinuria, the major risk factor for early atherosclerosis in juvenile-onset systemic lupus erythematosus.

Authors:  F Falaschi; A Ravelli; A Martignoni; D Migliavacca; M Sartori; A Pistorio; G Perani; A Martini
Journal:  Arthritis Rheum       Date:  2000-06

6.  C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Authors:  P M Ridker; C H Hennekens; J E Buring; N Rifai
Journal:  N Engl J Med       Date:  2000-03-23       Impact factor: 91.245

7.  Outcome after transplantation of young patients with systemic lupus erythematosus: a report of the North American pediatric renal transplant cooperative study.

Authors:  S M Bartosh; R N Fine; E K Sullivan
Journal:  Transplantation       Date:  2001-09-15       Impact factor: 4.939

8.  Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study.

Authors:  Thomas J Wang; Byung-Ho Nam; Peter W F Wilson; Philip A Wolf; Daniel Levy; Joseph F Polak; Ralph B D'Agostino; Christopher J O'Donnell
Journal:  Arterioscler Thromb Vasc Biol       Date:  2002-10-01       Impact factor: 8.311

Review 9.  Autoimmunity, oxidized LDL and cardiovascular disease.

Authors:  Johan Frostegård
Journal:  Autoimmun Rev       Date:  2002-08       Impact factor: 9.754

Review 10.  The epidemiology of systemic lupus erythematosus.

Authors:  Sònia Jiménez; Ricard Cervera; Josep Font; Miguel Ingelmo
Journal:  Clin Rev Allergy Immunol       Date:  2003-08       Impact factor: 8.667

View more
  20 in total

Review 1.  Improving outcomes in patients with lupus and end-stage renal disease.

Authors:  Antonio Inda-Filho; Joel Neugarten; Chaim Putterman; Anna Broder
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

2.  Increased hospitalizations and death in patients with ESRD secondary to lupus.

Authors:  S Sule; B Fivush; A Neu; S Furth
Journal:  Lupus       Date:  2012-06-26       Impact factor: 2.911

Review 3.  Pathogenesis and treatment of atherosclerosis in lupus.

Authors:  Maureen McMahon; Brian Skaggs
Journal:  Rheum Dis Clin North Am       Date:  2014-06-10       Impact factor: 2.670

4.  Racial and Ethnic Differences in Mortality and Cardiovascular Events Among Patients With End-Stage Renal Disease Due to Lupus Nephritis.

Authors:  Jose A Gómez-Puerta; Candace H Feldman; Graciela S Alarcón; Hongshu Guan; Wolfgang C Winkelmayer; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-10       Impact factor: 4.794

5.  Sex Disparities in Risk of Mortality Among Children With ESRD.

Authors:  Patrick Ahearn; Kirsten L Johansen; Charles E McCulloch; Barbara A Grimes; Elaine Ku
Journal:  Am J Kidney Dis       Date:  2018-10-11       Impact factor: 8.860

Review 6.  Mortality in Systemic Lupus Erythematosus: an Updated Review.

Authors:  César E Fors Nieves; Peter M Izmirly
Journal:  Curr Rheumatol Rep       Date:  2016-04       Impact factor: 4.592

7.  Three decades of progress in treating childhood-onset lupus nephritis.

Authors:  Tanya Pereira; Carolyn L Abitbol; Wacharee Seeherunvong; Chryso Katsoufis; Jayanthi Chandar; Michael Freundlich; Gastón Zilleruelo
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-28       Impact factor: 8.237

8.  Incidence of End-Stage Renal Disease Among Newly Diagnosed Systemic Lupus Erythematosus Patients: The Georgia Lupus Registry.

Authors:  Laura Plantinga; S Sam Lim; Rachel Patzer; William McClellan; Michael Kramer; Mitchel Klein; Stephen Pastan; Caroline Gordon; Charles Helmick; Cristina Drenkard
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-03       Impact factor: 4.794

9.  Association between antiphospholipid antibodies and all-cause mortality among end-stage renal disease patients with and without SLE: a retrospective cohort study.

Authors:  Anna Broder; Wenzhu B Mowrey; Mimi Kim; Irina Murakhovskaya; Henny Billett; Joel Neugarten; Karen H Costenbader; Chaim Putterman
Journal:  Rheumatology (Oxford)       Date:  2015-12-24       Impact factor: 7.580

Review 10.  Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention.

Authors:  Allison B Reiss; Benna Jacob; Saba Ahmed; Steven E Carsons; Joshua DeLeon
Journal:  Inflammation       Date:  2021-04-05       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.